Epoprostenol and Valsartan share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.222 means 22% of the combined target set is bound by both compounds. The IDF-weighted score of 0.139 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do Epoprostenol and Valsartan have in common?
Epoprostenol and Valsartan share 2 molecular targets with a Jaccard similarity of 22%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can Epoprostenol and Valsartan be combined?
Epoprostenol and Valsartan share 2 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: Epoprostenol or Valsartan?
Both Epoprostenol and Valsartan have substantial PubMed research. View their individual profiles for full evidence scores.